Celularity Inc. Form 8-K Summary
Business Context and Reporting Period
Celularity Inc. filed a Form 8-K dated November 21, 2023, reporting a Nasdaq listing compliance issue related to the delayed filing of its Form 10-Q for the quarter ended September 30, 2023.
Financial Metrics and Reporting Status
- The Q3 2023 Form 10-Q was not filed by the November 20, 2023 expiration of the Rule 12b-25 extension.
- The company stated that preparation of the financial statements, including goodwill impairment testing for the quarter ended September 30, 2023, had not been completed.
- The filing does not provide clear values for revenue, profit, cash flow, margins, debt, liquidity, or the amount of any goodwill impairment.
Material Changes and Listing Compliance
- Nasdaq notified the company on November 21, 2023 that it no longer complied with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports.
- The notice had no immediate effect on the listing or trading of the company’s Class A common stock or warrants, which continued to trade on the Nasdaq Capital Market under the symbols CELU and CELUW.
- Celularity must submit a compliance plan to Nasdaq by January 22, 2024. If the plan is accepted, the company may have until May 20, 2024 to regain compliance.
- The company was also previously noncompliant with Nasdaq’s minimum bid price requirement under Rule 5450(a)(1), with a stated deadline of March 11, 2024 to regain compliance.
Outlook, Risks, and Unusual Items
- The company intends to submit a plan to Nasdaq within the required 60-day period and will evaluate available options to regain compliance.
- There can be no assurance that the company will regain compliance within the applicable period or maintain compliance with other Nasdaq listing requirements.
- If the company uses a reverse stock split to address the minimum bid price deficiency, it must complete the action no later than 10 business days before March 11, 2024.
- Nasdaq may initiate delisting procedures if it determines that the deficiency cannot be cured or the company is otherwise ineligible.
Investor Verification Points
- Verify the eventual filing date and contents of the Q3 2023 Form 10-Q, including completion of goodwill impairment testing and any resulting charge.
- Monitor Nasdaq’s decision regarding the company’s compliance plan and any subsequent delisting notices.
- Confirm whether Celularity regained compliance with the minimum bid price requirement by March 11, 2024.
- Review any proposed or completed reverse stock split and its effects on shareholders.